The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

PURPOSE To provide evidence-based recommendations updating the 2017 ASCO
guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …

Importance Non–small cell lung cancer remains the leading cause of cancer death in the
United States. Until the last decade, the 5-year overall survival rate for patients with …

Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and
ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity …

Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has
shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive …